Phathom PharmaceuticalsPHAT +0.47%23 Market Cap is $850.2 Mil as of Jun. 25, 2026. GuruFocus rates PHAT with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,431 Biotechnology companies, Phathom Pharmaceuticals ranks better than 78.13% on this metric.
Phathom Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 ($836.2 Mil) to Dec. 2025 ($1,184.8 Mil) but then
declined
from Dec. 2025 ($1,184.8 Mil) to Mar. 2026 ($882.6 Mil).
Phathom Pharmaceuticals's annual market cap
increased
from Dec. 2023 ($529.3 Mil) to Dec. 2024 ($556.4 Mil) and
increased
from Dec. 2024 ($556.4 Mil) to Dec. 2025 ($1,184.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Phathom Pharmaceuticals's Enterprise Value for Today is $835.6 Mil.
Phathom Pharmaceuticals (NAS:PHAT) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Phathom Pharmaceuticals Market Cap Related Terms
Phathom Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Phathom Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phathom Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Phathom Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Phathom Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals (PHAT) has a Market Cap of $850.2 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Phathom Pharmaceuticals and its competitors. According to the industry distribution chart, Phathom Pharmaceuticals ranks #313 out of 1431 companies in the Biotechnology industry, placing it in the top 21.9%.
Is Phathom Pharmaceuticals' Market Cap too high?
Phathom Pharmaceuticals' current Market Cap is $850.2 Mil. The Biotechnology industry median Market Cap is 117.63. Phathom Pharmaceuticals' value of $850.2 Mil is 622.8% above this industry median. Based on the distribution chart, Phathom Pharmaceuticals ranks #313 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Phathom Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' Market Cap compare to AURA and RLMD?
According to the Biotechnology industry distribution chart, Phathom Pharmaceuticals ranks #313 out of 1431 companies for Market Cap. This places Phathom Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.63. Phathom Pharmaceuticals' value of $850.2 Mil is 622.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phathom Pharmaceuticals's current Market Cap of $850.2 Mil is 622.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Phathom Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phathom Pharmaceuticals's current Market Cap is $850.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Phathom Pharmaceuticals (PHAT) has a current Market Cap of $850.2 Mil. The current Market Cap is $850.2 Mil and 622.8% above the Biotechnology industry median of 117.63. Phathom Pharmaceuticals' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current Market Cap is $850.2 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
23GF Score
Get the complete analysis for PHAT
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAT has been successfully added to your 
